Etaracizumab

DB12213InvestigationalProtein Based Therapies

Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.

Mechanism: Pharmacologically active on Integrin beta-3 and Integrin alpha-V
Curator reviewed
Code names: MEDI-522

Resolves to

Compound

UNII41W9MFI160CAS892553-42-3

Targets

P05106ITGB3P06756ITGAV

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

9Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Etaracizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account